间充质干细胞治疗特发性肺纤维化的机遇与挑战OA

Idiopathic pulmonary fibrosis(IPF)is a degenerative disease characterized by irreversible fibrosis and connective tissue deposition in the lung tissue,commonly seen in people over the age of 50.Aging,genet-ic and environmental factors can trigger epigenetic changes,leading to the damage and abnormal activation of alveolar epithelial cells,which in turn cause fibrosis and are considered key to the occurrence of IPF.Howev-er,the specific etiology and pathogenesis are not yet clear,and the prognosis of the disease is poor,with no cure currently available.Cellular therapy has become an emerging treatment strategy for a variety of diseases.Mesenchymal stem cells(MSCs),with their strong self-renewal,multidirectional differentiation potential and immune regulation capabilities,and low tumorigenic risk,are of significant clinical value and can provide a new perspective for the treatment of IPF.This paper discussed the challenges and prospects of MSCs in the treatment of IPF,providing a reference for future research.